| Dr Jenni Conner Deleon, MD | |
|
1900 Woodland Dr, Coos Bay, OR 97420-0000 | |
| (541) 267-5151 | |
| (541) 266-4579 |
| Full Name | Dr Jenni Conner Deleon |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1900 Woodland Dr, Coos Bay, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215911045 | NPI | - | NPPES |
| 022756 | Medicaid | OR | |
| 1407812365 | Other | OR | NBMC NPI NUMBER-GROUP |
| 930635514 | Other | OR | GROUP TAX ID |
| R0000WFBTV | Other | OR | MEDICARE GROUP PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD25369 (Oregon) | Primary |
| Entity Name | North Bend Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407812365 PECOS PAC ID: 5597677716 Enrollment ID: O20031105000138 |
News Archive
Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. The researchers found that of nearly 80 high-risk devices, the majority received approval based on data from a single study.
A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.
At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
deCODE genetics has announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D).
› Verified 5 days ago
| Entity Name | Bay Area Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225016561 PECOS PAC ID: 2163331000 Enrollment ID: O20040310000301 |
News Archive
Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. The researchers found that of nearly 80 high-risk devices, the majority received approval based on data from a single study.
A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.
At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
deCODE genetics has announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jenni Conner Deleon, MD 1900 Woodland Dr, Coos Bay, OR 97420-0000 Ph: (541) 267-5151 | Dr Jenni Conner Deleon, MD 1900 Woodland Dr, Coos Bay, OR 97420-0000 Ph: (541) 267-5151 |
News Archive
Pre-market approval by the FDA of cardiovascular devices is often based on studies that lack adequate strength or may have been prone to bias, according to a study in the December 23/30 issue of JAMA. The researchers found that of nearly 80 high-risk devices, the majority received approval based on data from a single study.
A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.
At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
deCODE genetics has announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D).
› Verified 5 days ago
Dr. Donna Lee Rabin, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 Fax: 541-266-4501 | |
Kevin H Molteni, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 | |
Dr. Mary Lynn Moore, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1750 Thompson Rd, Coos Bay, OR 97420 Phone: 541-269-0333 Fax: 541-269-7389 | |
Dr. Cassandra Kay Hastings, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 Fax: 541-266-4566 | |
Dr. Kariktan Cruz, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 Fax: 541-266-4501 | |
Dr. Dale Preston Henken, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1900 Woodland Dr, Coos Bay, OR 97420 Phone: 541-267-5151 Fax: 541-266-4562 |